Undocumented source of pharmacy benefit manager revenue

Mark Siracuse, Bartholomew E. Clark, Robert I. Garis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose. The difference between what pharmacy benefit management companies (PBMs) charge prescription benefit plan sponsors and what dispensing pharmacies are paid ("spread") was studied. Methods. Data from prescription transaction invoices from two large employer groups, each using a different PBM, and 84 community pharmacies (which differed for each employer group due to clear geographic separation) participating in these plans between October 1, 2002, and December 31, 2004, were studied. Detailed community pharmacy payment transaction records were compared with PBM claim records from two employers. One employer provided 49,633 prescription claim records, and the other employer provided 120,684 prescription claim records. Spread between amount due billed to the employer by the PBM and amount due paid to the dispensing pharmacy by the PBM for all prescriptions, for brand-name prescriptions, and for generic prescriptions was analyzed. Results. For the two PBMs combined, the mean ± S.D. spread for 20,376 paid transactions was $1.82 ± $8.26 per prescription. The mean ± S.D. spread for brand-name prescriptions was $0.07 ± $5.18 and for generic medications was $4.20 ± $10.69 per prescription. The two PBMs differed significantly in their spread for all drugs ($2.30 ± $6.17 and $1.78 ± $8.40) and for brand-name drugs ($0.47 ± $3.21 and $0.04 ± $5.30). The difference between PBMs for spreads on generic medications did not achieve statistical significance. Conclusion. Wide variations in spread pricing existed between two PBMs and between brand-name and generic medications. Pharmacists and prescription benefit plan sponsors should be aware of this discrepancy and seek a more transparent contract with PBMs.

Original languageEnglish
Pages (from-to)552-557
Number of pages6
JournalAmerican Journal of Health-System Pharmacy
Volume65
Issue number6
DOIs
StatePublished - Mar 15 2008

Fingerprint

Prescriptions
Names
Pharmacies
Contracts
Pharmacists
Pharmaceutical Preparations
Costs and Cost Analysis

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Leadership and Management
  • Medicine(all)

Cite this

Undocumented source of pharmacy benefit manager revenue. / Siracuse, Mark; Clark, Bartholomew E.; Garis, Robert I.

In: American Journal of Health-System Pharmacy, Vol. 65, No. 6, 15.03.2008, p. 552-557.

Research output: Contribution to journalArticle

Siracuse, Mark ; Clark, Bartholomew E. ; Garis, Robert I. / Undocumented source of pharmacy benefit manager revenue. In: American Journal of Health-System Pharmacy. 2008 ; Vol. 65, No. 6. pp. 552-557.
@article{be9521acd3e94cb08232927ec2702421,
title = "Undocumented source of pharmacy benefit manager revenue",
abstract = "Purpose. The difference between what pharmacy benefit management companies (PBMs) charge prescription benefit plan sponsors and what dispensing pharmacies are paid ({"}spread{"}) was studied. Methods. Data from prescription transaction invoices from two large employer groups, each using a different PBM, and 84 community pharmacies (which differed for each employer group due to clear geographic separation) participating in these plans between October 1, 2002, and December 31, 2004, were studied. Detailed community pharmacy payment transaction records were compared with PBM claim records from two employers. One employer provided 49,633 prescription claim records, and the other employer provided 120,684 prescription claim records. Spread between amount due billed to the employer by the PBM and amount due paid to the dispensing pharmacy by the PBM for all prescriptions, for brand-name prescriptions, and for generic prescriptions was analyzed. Results. For the two PBMs combined, the mean ± S.D. spread for 20,376 paid transactions was $1.82 ± $8.26 per prescription. The mean ± S.D. spread for brand-name prescriptions was $0.07 ± $5.18 and for generic medications was $4.20 ± $10.69 per prescription. The two PBMs differed significantly in their spread for all drugs ($2.30 ± $6.17 and $1.78 ± $8.40) and for brand-name drugs ($0.47 ± $3.21 and $0.04 ± $5.30). The difference between PBMs for spreads on generic medications did not achieve statistical significance. Conclusion. Wide variations in spread pricing existed between two PBMs and between brand-name and generic medications. Pharmacists and prescription benefit plan sponsors should be aware of this discrepancy and seek a more transparent contract with PBMs.",
author = "Mark Siracuse and Clark, {Bartholomew E.} and Garis, {Robert I.}",
year = "2008",
month = "3",
day = "15",
doi = "10.2146/ajhp070389",
language = "English",
volume = "65",
pages = "552--557",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "6",

}

TY - JOUR

T1 - Undocumented source of pharmacy benefit manager revenue

AU - Siracuse, Mark

AU - Clark, Bartholomew E.

AU - Garis, Robert I.

PY - 2008/3/15

Y1 - 2008/3/15

N2 - Purpose. The difference between what pharmacy benefit management companies (PBMs) charge prescription benefit plan sponsors and what dispensing pharmacies are paid ("spread") was studied. Methods. Data from prescription transaction invoices from two large employer groups, each using a different PBM, and 84 community pharmacies (which differed for each employer group due to clear geographic separation) participating in these plans between October 1, 2002, and December 31, 2004, were studied. Detailed community pharmacy payment transaction records were compared with PBM claim records from two employers. One employer provided 49,633 prescription claim records, and the other employer provided 120,684 prescription claim records. Spread between amount due billed to the employer by the PBM and amount due paid to the dispensing pharmacy by the PBM for all prescriptions, for brand-name prescriptions, and for generic prescriptions was analyzed. Results. For the two PBMs combined, the mean ± S.D. spread for 20,376 paid transactions was $1.82 ± $8.26 per prescription. The mean ± S.D. spread for brand-name prescriptions was $0.07 ± $5.18 and for generic medications was $4.20 ± $10.69 per prescription. The two PBMs differed significantly in their spread for all drugs ($2.30 ± $6.17 and $1.78 ± $8.40) and for brand-name drugs ($0.47 ± $3.21 and $0.04 ± $5.30). The difference between PBMs for spreads on generic medications did not achieve statistical significance. Conclusion. Wide variations in spread pricing existed between two PBMs and between brand-name and generic medications. Pharmacists and prescription benefit plan sponsors should be aware of this discrepancy and seek a more transparent contract with PBMs.

AB - Purpose. The difference between what pharmacy benefit management companies (PBMs) charge prescription benefit plan sponsors and what dispensing pharmacies are paid ("spread") was studied. Methods. Data from prescription transaction invoices from two large employer groups, each using a different PBM, and 84 community pharmacies (which differed for each employer group due to clear geographic separation) participating in these plans between October 1, 2002, and December 31, 2004, were studied. Detailed community pharmacy payment transaction records were compared with PBM claim records from two employers. One employer provided 49,633 prescription claim records, and the other employer provided 120,684 prescription claim records. Spread between amount due billed to the employer by the PBM and amount due paid to the dispensing pharmacy by the PBM for all prescriptions, for brand-name prescriptions, and for generic prescriptions was analyzed. Results. For the two PBMs combined, the mean ± S.D. spread for 20,376 paid transactions was $1.82 ± $8.26 per prescription. The mean ± S.D. spread for brand-name prescriptions was $0.07 ± $5.18 and for generic medications was $4.20 ± $10.69 per prescription. The two PBMs differed significantly in their spread for all drugs ($2.30 ± $6.17 and $1.78 ± $8.40) and for brand-name drugs ($0.47 ± $3.21 and $0.04 ± $5.30). The difference between PBMs for spreads on generic medications did not achieve statistical significance. Conclusion. Wide variations in spread pricing existed between two PBMs and between brand-name and generic medications. Pharmacists and prescription benefit plan sponsors should be aware of this discrepancy and seek a more transparent contract with PBMs.

UR - http://www.scopus.com/inward/record.url?scp=41049096757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41049096757&partnerID=8YFLogxK

U2 - 10.2146/ajhp070389

DO - 10.2146/ajhp070389

M3 - Article

VL - 65

SP - 552

EP - 557

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 6

ER -